Home Studieinformatie Studies open voor inclusie

Acute myeloïde leukemie (AML)

EORTC1301: InDACtion vs. induction: 10-day decitabine versus conventional chemotherapy (3+7) followed by allografting in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Chronische myeloïde leukemie (CML)

Muscle function: The relation between muscle function and muscle pain in patients with chronic myeloid leukemia (CML): a pilot study

CMyLife effectmeting: The impact of CMyLife on quality of life, information supply, patient empowerment and guideline and medication adherence in patients with CML

Zorgpad analyse CML: Pathways of care that lead to a sustained and deep treatment response in chronic myeloid leukemia

Chronische lymfatische leukemie (CLL)

HOVON 140: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (Rve) versus obinutuzumab (GA101) plus venetoclax (Gve) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del (17P) or TP53 mutation

Myelodysplastisch syndroom (MDS)

EU-MDS: A prospective, multicentre European registry for newly diagnosed patients with myelodysplastic syndromes (MDS), including acute myeloid leukaemia with 20-30 percent marrow blasts (former RAEB-t), and chronic myelomonocytic leukaemia (CMML)

Kaleidoscope: A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q) 

Myeloproliferatieve neoplasieën (MPN)

HOVON 134: A phase II trial in patients with myelofibrosis (primary, post-ET or post-PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation

PV-NIS: An international multi-centric observational study on the use of ruxolitinib in the treatment of patients with polycythemia vera resistant or intolerant to hydroxyurea

Non-Hodgkin lymfomen (NHL)

HOVON 119: Efficacy of alternating immunochemotherapy consisting of R-CHOP + RHAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma

HOVON 127: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

HOVON 133 / TRIANGLE: Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma – A randomized European MCL network trial

HOVON 900: A national MYC screening study for newly diagnosed DLBCL patients

Multipel myeloom (MM)

HOVON 114: Pomalidomide combined with carfilzomib and dexamethasone (PCd) for induction and consolidation followed by pomalidomide combined with dexamethasone vs pomalidomide maintenance for patients with multiple myeloma in first relapse after prior 1st line treatment with lenalidomide and bortezomib

NivoDara: A phase 2 study of nivolumab combined with daratumumab with or without low-dose cyclophosphamide in relapsed/refractory multiple myeloma

Stamceltransplantatie (SCT)

PSCT19: Vaccination with PD-L1/L2-silenced minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I/II study)

Supportive care

ORASTEM: Oral complications in patients treated with hematopoietic stem cell transplantation

PIRANA: Pharmacokinetics of posaconazole (Noxafil) as treatment for invasive fungal infections

PACER: A randomized controlled trial on prophylactic platelet transfusion prior to central venous catheter placement in patients with trombocytopenia

AzoR-Man: PCR based detection of azole resistance in A. fumigatus to improve patient outcome. A prospective multicentre intervention study

AFFECT-1: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of mucositis and fever during neutropenia in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan

SPARKLE: Improving sleep quality, psychosocial functioning and cancer related fatigue with light therapy


PRO-RBDD: Prospective data collection on patients with rare bleeding disorders

RBiN: Rare bleeding disorders in the Netherlands

HemoNED: Landelijk register van patiënten met hemofilie en aanverwante aandoeningen

EUHASS: European haemophilia safety surveillance system registry

OPTI-CLOT: Peri-operative pharmacokinetic-guided dosing of clotting factor in hemophilia

DAVID: DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A

Little DAVID: Desmopressin and FVIII concentrate combination treatment in non-severe hemophilia A patients undergoing minor interventions

HiN-6: Haemophilia in the Netherlands 6

Obizur EU PASS: Prospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice

DYNAMICS: The Dynamic interplay between bleeding phenotype and baseline factor level in moderate and mild hemophilia A and B

Observational study on pregnancy outcome in women with inherited bleeding disorders


PPI Shine Again: Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial


STARRING: Sickle cell disease: targeting alloantibody formation reduction; risk factors, and genetics

Paroxysmale nachtelijke hemoglobinurie (PNH)

RPNH01: Paroxysmal nocturnal hemoglobinuria (PNH) registry

AK581: Akari long term safety coversin

Ga terug naar de algemene homepage Studieinformatie.